Figure 6
Atg7 knockdown improves antileukemic activity of Ara-C in OCI AML3 in NSG model of engrafting leukemia. NOD-SCID-IL2Rϒ null mice were injected with Atg7 knockdown or ShControl OCI-AML3 (1 × 106) through tail vein and Ara-C (100 mg/kg) administered on days 7, 9, 11, 14, 16, 18, and 24 through intraperitoneal route. At day 29, 50 μL of PB was collected from intraorbital bleeding and tumor burden was measured by detection of double-positive (GFP/human CD45) cells (A). Two mice from each group were euthanized to assess splenomegaly (C) and infiltration of tumor in other organs (D). A plot of overall survival probability, estimated with the Kaplan-Meier method, is shown in (B). Original magnification ×40 for panel D.

Atg7 knockdown improves antileukemic activity of Ara-C in OCI AML3 in NSG model of engrafting leukemia. NOD-SCID-IL2Rϒ null mice were injected with Atg7 knockdown or ShControl OCI-AML3 (1 × 106) through tail vein and Ara-C (100 mg/kg) administered on days 7, 9, 11, 14, 16, 18, and 24 through intraperitoneal route. At day 29, 50 μL of PB was collected from intraorbital bleeding and tumor burden was measured by detection of double-positive (GFP/human CD45) cells (A). Two mice from each group were euthanized to assess splenomegaly (C) and infiltration of tumor in other organs (D). A plot of overall survival probability, estimated with the Kaplan-Meier method, is shown in (B). Original magnification ×40 for panel D.

Close Modal

or Create an Account

Close Modal
Close Modal